Geron Corp. (NASDAQ:GERN) shares rose 1.8% during mid-day trading on Wednesday . The stock traded as high as $2.80 and last traded at $2.78, with a volume of 786,227 shares traded. The stock had previously closed at $2.73.

GERN has been the subject of several research reports. BTIG Research initiated coverage on shares of Geron Corp. in a research report on Friday, August 19th. They issued a “neutral” rating for the company. Zacks Investment Research lowered shares of Geron Corp. from a “hold” rating to a “sell” rating in a research report on Tuesday, May 10th. Finally, FBR & Co reiterated a “buy” rating on shares of Geron Corp. in a research report on Sunday, May 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $6.20.

The firm has a market capitalization of $425.70 million and a price-to-earnings ratio of 334.375. The stock’s 50 day moving average is $2.70 and its 200-day moving average is $2.81.

Geron Corp. (NASDAQ:GERN) last released its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.07) by $0.02. During the same quarter in the previous year, the business posted ($0.06) earnings per share. The business earned $0.21 million during the quarter, compared to the consensus estimate of $0.38 million. The firm’s revenue was down 15.9% on a year-over-year basis. Equities research analysts anticipate that Geron Corp. will post ($0.23) EPS for the current year.

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.